Related Experiment Video
Updated: Dec 10, 2025

An Affordable HIV-1 Drug Resistance Monitoring Method for Resource Limited Settings
Published on: March 30, 2014
PrEP Nonadherence, White Coat Dosing, and HIV Risk Among a Cohort of MSM
Cheríe S Blair1, Matthew R Beymer2, Ryan M Kofron3
1Division of Infectious Diseases, David Geffen School of Medicine at UCLA, Los Angeles, California, USA.
Abstract:
Among a cohort of men who have sex with men in a pre-exposure prophylaxis (PrEP) adherence trial, syphilis requiring treatment was associated with white coat dosing (increased PrEP adherence immediately preceding study visits) when compared with participants with optimal drug concentrations. The findings highlight the need for identifying and reducing barriers to PrEP adherence.
Related Concept Videos
Drug Dosing: Obese Patients
Coronary Artery Disease IV: Preventive Measures
Bioavailability Study Design: Healthy Subjects Versus Patients
Factors Affecting the Risk of Infection
The integrity and count of the white blood cells help the body resist pathogens and fight infection. When impaired, it reduces the body's resistance to pathogens. The acidic pH levels of the gastrointestinal, genitourinary tracts, and skin...
Sexually Transmitted Infections
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...

